SCHEMBL10116366

SCHEMBL10116366

CC(C)(C)S(=O)(=O)Nc1ccc(C(=O)Nc2ccc(F)c(C(F)(F)F)c2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
NPSR1 Q6W5P4 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
AR P10275 1/20 0.51
HTT P42858 1/20 0.51
XBP1 P17861 1/20 0.50
GRM4 Q14833 1/20 0.50
KCNQ3 O43525 1/20 0.50
KCNQ2 O43526 1/20 0.50
KCNE1 P15382 1/20 0.50
KCNQ1 P51787 1/20 0.50
LMNA P02545 3/20 0.47
SLC22A12 Q96S37 1/20 0.47
TP53 P04637 1/20 0.47
TRPV1 Q8NER1 1/20 0.46
BRAF P15056 1/20 0.44
KDR P35968 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116345 0.87 NPC1 (0.58) MAPTNPSR1MEN1KMT2ANPC1
SCHEMBL10116351 0.85 KMT2A (0.51) MAPTNPSR1MEN1KMT2ANPC1
SCHEMBL10116659 0.84 MAPT (0.50) MAPTNPSR1MEN1KMT2ANPC1
SCHEMBL10116360 0.84 TRPV1 (0.47) MAPTNPSR1MEN1KMT2ANPC1
SCHEMBL10116438 0.83 MAPT (0.46) MAPTNPSR1MEN1KMT2ANPC1
SCHEMBL10116364 0.82 MAPT (0.53) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL10116449 0.82 LMNA (0.48) MEN1KMT2ANPC1RAB9AHTT
SCHEMBL10114489 0.82 TRPV1 (0.68) MAPTNPSR1MEN1KMT2ANPC1
SCHEMBL10116240 0.81 MEN1 (0.55) MAPTNPSR1MEN1KMT2ANPC1
SCHEMBL10116349 0.81 MEN1 (0.49) MAPTNPSR1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R MAPT 3602/4885NPSR1 7/4885MEN1 2876/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MAPT 3367/4885NPSR1 8/4885MEN1 2932/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MAPT 3683/4885NPSR1 7/4885MEN1 2926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.